A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Study of Vedolizumab in Subjects Undergoing Stem Cell Transplantation
Sponsor: Millennium Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS3849
U.S. Govt. ID: NCT03657160
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purpose of this research study is to investigate if a drug called Vedolizumab is safe and effective in preventing acute graft-versus-host disease (attack of donor cells on recipient healthy organs after transplant) of the gut in comparison to placebo (dummy drug). This will be studied in patients undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) from an unrelated donor for a blood cancer such as acute leukemia, chronic myelogenous leukemia, myelo fibrosis, or other myeloproliferative disorder.
This study is closed
Ran Reshef, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with leukemia, myelofibrosis, or other myeloproliferative disorder? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator